Novo pays Hengrui $300M upfront for oral GLP-1/GIP candidate HRS-1596
The preclinical dual agonist is designed for once-weekly oral dosing, a schedule no marketed or late-stage incretin pill currently offers.
TR
By Tom Reyes · Markets Editor
Sep 29 03:50 ETSource: Fierce Biotech
The wire
- 01Novo Nordisk takes ex-China rights to Hengrui Pharma's HRS-1596 for $300 million upfront and up to $2.6 billion in total milestones, announced September 29.
- 02HRS-1596 targets obesity, type 2 diabetes and other metabolic disease; Novo says once-weekly oral dosing could cut dosing frequency versus injectable Zepbound or daily oral rivals.
- 03The asset is preclinical with Chinese clearance for phase 1 only, so human data are years away; Novo struck the deal amid disappointing readouts and a pipeline rebuild.
From the source
Read at fiercebiotech.comNovo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui
Novo’s ongoing attempts to rejuvenate its pipeline have seen the Big Pharma turn to one of the most in-demand drug developers in China.
